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Lymphokines like IL-1 are of multicelTular origin, and through their multifa- 
ceted regulatory actions they affect a variety of different target cells during host 
response  to infections.  IL-1  at  the  site of inflammation activates  lymphocytes, 
granulocytes, and fibroblasts (1). Moreover, IL-1 also may act as mediator of the 
acute-phase response, promote catabolism of structural protein and matrix, and 
regulate the febrile response (1). To further elucidate these multiple biological 
effects on different tissues  and  to investigate whether they are  regulated by a 
single  entity  or  a  family  of related  molecules,  it  is  necessary  to  analyze  the 
sequence of the IL-1  molecule and to develop antibodies directed against  IL-1. 
The sequence of murine  IL-1 recently has  been discovered (2), and cloning of 
two distinct human IL-1 cDNAs has also been reported (3, 4). However, to date, 
only conventional antisera directed against IL-1 (1, 5) are available. In this study, 
an mAb that binds different IL-1 species and blocks the biological effects of IL- 
l  was developed and characterized. 
Materials and  Methods 
Preparation oflL-1  and Bioassays.  IL-1  was prepared from human adherent cells as 
described (6). Concentrated samples (100 t~l) were subjected to HPLC using Bio-Sil TSK 
125  (Bio-Rad,  Richmond, CA) size-exclusion chromatography or chromatofocusing on 
Mono P (Pharmacia Fine Chemicals, Upsala, Sweden) as described (6). 
For the detection of IL-1 activity, the thymocyte costimulator assay or the fibroblast 
(CRL 1445) proliferation assay were used (7). IL-2 activity was measured using an IL-2- 
dependent cytotoxic T  cell line (CTLL) (7), and IL-3 activity was evaluated using an IL- 
3-dependent cell line (32 DCL) (8). 
Immunization and Cell Fusion Procedures.  BALB/c mice were injected with six doses 
of partially purified (TSK 125 pool) IL-1 (40,000 U/ml) in complete Freund's adjuvant 
at 2 wk intervals over a period of 3 too. 3 d after the last immunization, splenocytes (1.5 
×  10 ~) from an immunized mouse that exhibited plasma anti-IL-1 activity were fused with 
1.5  ×  I0  ~ plasmocytoma cells (P~-X63-A~ 8-653, SP3) (9).  Subsequently, the ceils were 
resuspended in HAT selection medium, and 106 cells/well were plated into 96-well tissue 
culture plates. After 2 wk, cell cultures that produced I L-1 activity-inhibiting supernatants 
were expanded and cloned by a limiting-dilution method. Subsequently, the clones were 
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retested for inhibiting activity and injected i.p. into BALB/c mice that had been primed 
with 0.5  ml  of 2,  6,  10,  14-tetramethylpentadecane (Pristane;  Aldrich  Chemical Co. 
Milwaukee, WI). 
Preparation and Purification  ofmAb.  Each mAb was precipitated from clarified ascites 
fluid by the gradual addition of saturated ammonium sulfate to 45% saturation. Precipi- 
tated proteins were dissolved and dialyzed against several changes of PBS. IgG mAb were 
purified further by affinity chromatography using goat anti-mouse IgG (Nordic Immu- 
nology, Tilburg, The Netherlands) coupled to CNBr-activated Sepharose 4 B (9). The Ig 
class was determined by a dot immunobinding assay using anti-mouse Ig antisera (10). 
Preparation of an lmmunoaffinity Gel  for IL-1.  Monoclonal anti-IL-1 (40 t~g) was coupled 
to (2 ml) CNBr-activated Sepharose 4 B as described (9), and incubated 30 rain at 37°C 
with  different preparations  of IL-1.  Subsequently,  the  residual  IL-1  activity  in  the 
supernatant was measured in the thymocyte assay. 
Immune Precipitation  of BiosyntheticaUy Labeled IL-I.  2  X  107 peripheral blood mono- 
nuclear cells (PBMNC) were incubated with LPS (10 t~g/mt, from E. coli; Difco Labora- 
tories, Detroit, MI) in serum-free Eagle's MEM.  After 2 h  incubation, the supernatant 
was replaced by medium containing 14C-labeled amino acid mixture (12.5  t~Ci/ml), and 
incubation was continued for further 24 h. Subsequently, intraceUular lysate as well as 
extracellular supernatant IL-1  was immunoprecipitated as described (11). Proteins were 
eluted by boiling the samples in electrophoresis sample buffer and applied to 15% SDS- 
PAGE (12). The gel was screened for radioactivity by using a TLC scanner (Berthold, 
Vienna, Austria) (13). 
Results 
Hybridoma supernatants were assayed for anti-IL-1  activity by testing their 
capacity to block IL-l-mediated thymocyte proliferation. After recloning, super- 
natants obtained from nine clones inhibited ]L-1 activity (data not shown). Two 
of these  clones,  AK  7  and  AK  17,  were  reexpanded  and  selected  for  ascites 
production. Both ascitic antibodies were of the IgG2a class. 
IL-1  antibodies  purified  by affinity chromatography  suppressed  both  IL-1- 
mediated thymocyte and fibroblast proliferation (Fig. 1). In contrast, nonspecific 
IgG or SP3 cell supernatant did not inhibit the effect of IL-1 on thymocytes or 
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FICURE  l.  Effect ofanti-lL-I lgG on 1L-I activities. Serial triplicate dilutions of monoclonal 
anti-I L-1 IgG2a (AK 17) purified by affinity chromatography, and nonimmune murine IgG2a 
(IgG n.i.)  were tested in microtiter plates for their capacity to inhibit IL-1 (50 U/ml) -mediated 
thymocyte or  fibroblast  proliferation.  Results are expressed  as percentage  of |L-1  activity 
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fibroblasts.  The inhibitory effect of the antibody was dose related, and 0.5-1 
~g/ml anti-IL-I  IgG sufficed to completely inhibit the activity of 50  U/rot of 
partially purified 1L-1. 
To  confirm  the  specificity  of anti-IL-1  IgG,  its  effect  on  epidermal  cell 
thymocyte-activating factor (ETAF),  IL-2, and IL-3 activity was tested. ETAF 
was  derived  from  a  human  squamous  cell  carcinoma cell  line  (7),  IL-2  was 
prepared from human PBL as described (14), and IL-3 was obtained from the 
murine monomyelocytic WEHI 3 cell line (8). Monoclonal anti-IL-1 significantly 
inhibited  the  thymocyte proliferation  in  response  to  ETAF,  which  further 
supports  previous  data  (7)  showing  that  ETAF  and  IL-1  are  closely related 
moieties sharing similar antigenic structures. In contrast, anti-IL-1  IgG failed to 
inhibit the IL-2-dependent proliferation of CTLL  cells, nor did the antibody 
block the growth of the IL-3-dependent 32 DCL cells (Table I). 
The efficiency of anti-IL-1  IgG binding to IL-1  was tested by the capacity of 
anti-IL-1  IgG to  precipitate biosynthetically radiolabeled IL-1.  Human mono- 
nuclear cells were stimulated with LPS and incubated for 24 h with ~4C-labeled 
amino acids.  Subsequently, extracellular (supernatant)  as  well as  intracellular 
(cell lysate) IL-1 were immunoprecipitated with anti-IL-1  IgG (AK 17), and the 
precipitates were analyzed by SDS-PAGE. Immune IgG precipitated three radio- 
labeled proteins with molecular masses of 33,  17, and 4  kD, which correspond 
exactly to the molecular masses of the different species of human IL-1 and were 
present in supernatant as well as lysate of mononuclear cells (Fig. 2). 
Because monoclonal anti-IL-I  has been shown to be capable of precipitating 
IL-1, we wished to determine whether the antibody (AK 17) would facilitate the 
purification  of IL-1  by  preparing  an  immunoadsorbent column.  IL-1  (95%) 
bound to the immunoaffinity gel and was not released by washing with PBS. To 
elute the specifically bound material, a 3 M KSCN solution was used. The yield 
of IL-1 after immunoaffinity chromatography was ~20%. The final product had 
a specific activity of ~ 107 U/mg protein. Upon HPLC gel filtration, immunoaf- 
finity-purified IL-1 consistently eluted as a single peak of activity with a molecular 
mass of ~4 kD (Fig. 3). 
Discussion 
This  paper  outlines  the  development of mAb  that  appears  to  be  directed 
against IL-1 and ETAF of human origin. The antibody neutralizes the biological 
activities of IL-1,  as shown by its ability to block  IL-l-mediated thymocyte as 
well as fibroblast proliferation. Moreover, anti-IL-1 also binds to IL-1, evidencing 
the adjacency of the epitope recognized by anti-IL-1 to the active site on the IL- 
TABLE  I 
Specificity of Anti-IL-1 Neutralization  Assay 
Factor*  Cell source 
Nonimmune lgG (~g/ml)  Ak 17 anti-IL-I lgG 0~g/ml) 
1  0.5  0.25  1  0.5  0.25 
IL-l (100 U/ml)  Adherent cells  17,653  15,316  18,253  [,095  2,760  5,122 
ETAF (50 U/ml)  SCC cells  5,724  6,002  5,934  803  1,978  4,024 
IL-2 (100 U/ml)  Nonadherent cells  25,834  27,037  26,854  25,543  26,894  27,105 
IL-3 (100 U/ml)  WEHI 3 cells  13,741  13,053  12,983  13,657  12,573  12,881 
Results are expressed as mean cpm of triplicate  cultures, 
* Factors were partially purified  by HPLC gel filtration  on TSK 125. 466  KOCK  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  2.  SDS-PAGE  of  in  vivo-labeled  IL-1.  lmmunoprecipitation  of  biosynthetically 
labeled IL-I.  Autoradiogram of labeled proteins remaining in supernatant (A) or cell lysate 
(B) after precipitation with anti-IL-1 IgG2a (AK 17) The gel was screened for radioactivity by 
using a TLC scanner as described in Materials and Methods. 
1 molecule. Since anti-IL-1  IgG also was capable of neutralizing ETAF activity, 
the  hypothesis is  further supported  that  ETAF  and  IL  1  are  closely related 
moieties, which share similar antigenic structures, though they are released by 
different cell types. The inhibitory effect of the antibody was not cytotoxic, since 
it did not inhibit the proliferation of several cell lines tested (data not shown), 
and it did not interfere with IL-2 or IL-3 activity. 
Although the molecular structure of human IL-1 is not yet fully understood, 
the different molecular mass species of IL-1 may be proteolytic cleavage products 
of  a high molecular mass precursor IL-1 molecule (4). Upon immunoprecipitation 
of biosynthetically radiolabeled IL-1, the antibody reacted with all three of the 
different species of IL-1. In addition, immunoprecipitation of intracellular IL-1 
yielded large  amounts  of the  33  kD  IL-1,  whereas  if extracellular  IL-1  was 
precipitated with anti-IL-1  IgG, only minute amounts of high molecular mass 
IL-1 were detected. In the supernatant, proteolytically cleaved 17 kD and 4 kD 
IL-1 molecules were found in larger amounts. This again supports the concept 
that human IL-1  is synthesized as a  higher molecular mass precursor, which is 
subsequently enzymatically converted to the low molecular mass forms, as has 
been proposed (2). KOCK  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 3.  HPLC gel filtration (Bio-Sil TSK  125) of human mononuclear cell-derived IL-1 
purified by immunoaffinity chromatography  using anti-IL-1  lgG (Ak  17).  IL-1  activity was 
measured  using  the  thymocyte assay,  and  results  are  expressed  in  U/ml  IL-1  activity.  In 
addition,  the  column  eluent  was  monitored  on  a  Uvicon  720  LC  UV-visible wavelength 
detector. 
It is especially noteworthy that immunoaffinity-purified  IL-1  exhibited a  mo- 
lecular  mass of ~4  kD.  Therefore,  monoclonal  anti-IL-1  IgG appears  to react 
with  a  biologically active  low molecular  mass breakdown  product  of the  IL-1 
molecule. Biologically active 4 kD IL-1 molecules have also been detected in vivo 
(1,  15), suggesting that the active site is located in the part of the IL-1  molecule 
that apparently is recognized by the monoclonal anti-IL-1  IgG. 
Since  anti-IL-1  IgG  reacts  with  the  active  site  of IL-1  molecule,  it  may be 
useful to localize the amino acid sequence within the protein that are responsible 
for the biological activity. Moreover, the antibody may help to determine whether 
both  of the  recently described  (4)  human  IL-ls,  IL-lo~ and  IL-1/3,  which  are 
different  in  their  amino  acid  sequences share  a  common  area  responsible  for 
their  biological  functions.  This  reagent  could  also  be  helpful  in  determining 
whether  the  multiplicity  of the  biological  effects of IL-1  are  due to the  same 
moiety. Because there is some homology between IL-lo~ and IL-1/3, and murine 
IL-1 (4), it may also be that the active site is identical in human and murine IL- 
l.  This  is also supported  by our finding  that  anti-human  IL-1  IgG blocks the 
biological effect of murine IL-1 (our unpublished observations). In vivo, anti-IL- 
l  IgG may also prove useful for the investigation of the role of IL-1 during the 
pathogenesis of immunological as well as inflammatory diseases. 
Summary 
Human  IL-1  was successfully used  to produce an  anti-IL-1  mAb.  Anti-IL-1 
(IgG2a) blocked IL-l-mediated  thymocyte and  fibroblast proliferation,  but did 
not interfere  with  the  biological effects of other  lymphokines,  such as IL-2 or 
IL-3.  The  antibody  immunoprecipitated  biosynthetically  radiolabeled  33,  17, 
and 4 kD IL-1. An immunoadsorbent column yielded 20% of initial activity, and 
upon HPLC size-exclusion chromatography, affinity-purified IL-1  had a molec- 468  KC)CK ET  AL.  BRIEF  DEFINITIVE REPORT 
ular mass of ~4  kD.  These results provide first evidence of a  monoclonai anti- 
IL-1 that reacts with different species of IL-1 and apparently binds to an epitope 
close  to  the  active  site  of IL-1.  Thus,  anti-IL-1  IgG  may be  very  helpful  for 
further investigations of the molecular as well as biological characteristics of IL- 
l  and related mediators. 
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